Is Selinisol/Silvio used to treat hematological tumors as a targeted drug?

Selinexor is a new drug for the treatment of hematological tumors. It is not a targeted drug in the traditional sense. Seleniso exerts its therapeutic effect mainly by inhibiting the function of XPO1 (Exportin 1) protein, which is a nucleocytoplasmic transport protein responsible for transporting specific proteins from the nucleus to the cytoplasm. In many cancer types, XPO1 dysfunction may lead to abnormal trafficking of tumor suppressors and other key proteins, thereby accelerating cancer cell proliferation and metastasis.

Selinesol restores the function of these tumor suppressors by directly inhibitingXPO1, slowing or stopping the growth of tumor cells. It is classified as a "nuclear transport inhibitor" and is different from traditional targeted drugs. Although targeted drugs usually work by inhibiting specific receptors, enzymes or signaling pathways on or inside tumor cells, selinesol has a unique mechanism of action. It does not directly act on surface receptors on tumor cells, but regulates the occurrence and development of tumors by affecting the transport of intracellular proteins.

Selinisol has shown promising results against blood cancers, particularly multiple myeloma (MM) and certain types of lymphoma. It is often combined with other drugs, such as bortezomib and dexamethasone, to enhance its anti-tumor effects. This mechanism of selinesol makes it a new treatment option, especially for patients with relapsed or refractory hematological cancers that are refractory to traditional treatments. It provides a new treatment direction.

Although the therapeutic mechanism of selinesol is different from traditional targeted drugs, its role is still to regulate the growth of tumor cells through precise molecular mechanisms. Therefore, although it does not fall under the traditional definition of a targeted drug, it is still an anticancer drug with targeted properties.

Keyword tags: Selinexor, Selinexor, Selinexor, nuclear transport inhibitors, targeted drugs, hematological tumors, cancer treatment, multiple myeloma, lymphoma

Reference materials:https://www.xpovio.com/